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Heart valve structures derived from mesenchymal cells of the endocardial cushions (ECs) are composed of highly organized cell lineages and
extracellular matrix. Sox9 is a transcription factor required for both early and late stages of cartilage formation that is also expressed in the
developing valves of the heart. The requirements for Sox9 function during valvulogenesis and adult valve homeostasis in mice were examined by
conditional inactivation of Sox9 using Tie2-cre and Col2a1-cre transgenes. Sox9 flox/flox;Tie2-cre mice die before E14.5 with hypoplastic ECs,
reduced cell proliferation and altered extracellular matrix protein (ECM) deposition. Sox9 flox/flox;Col2a1-cre mice die at birth with thickened heart
valve leaflets, reduced expression of cartilage-associated proteins and abnormal ECM patterning. Thickened valve leaflets and calcium deposits,
characteristic of valve disease, are observed in heterozygous adult Sox9 flox/+;Col2a1-cre mice. Therefore, Sox9 is required early in valve
development for expansion of the precursor cell population and later is required for normal expression and distribution of valvular ECM proteins.
These data indicate that Sox9 is required for early and late stages of valvulogenesis and identify a potential role for Sox9 in valve disease
mechanisms.
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Congenital heart defects are among the most common
developmental anomalies and often include malformations of
valve structures; however, the origins of these abnormalities are
not well known (Hoffman and Kaplan, 2002). During
embryonic development, heart valve formation begins in the
atrioventricular (AV) canal and outflow tract (OFT) with
endothelial to mesenchymal cell transformation (EMT) and
subsequent formation of endocardial cushions (ECs) (Arm-
strong and Bischoff, 2004; Person et al., 2005). Newly
transformed mesenchymal cells continue to proliferate and
diversify into distinct cell lineages that form mature heart valve
leaflets and supporting chordae tendineae (Armstrong and⁎ Corresponding author. Fax: +1 513 636 5958.
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doi:10.1016/j.ydbio.2007.02.002Bischoff, 2004; Lincoln et al., 2004, 2006c; Person et al., 2005).
The mature heart valve structures are highly organized and
express specific extracellular matrix (ECM) proteins character-
istic of cartilage in the valve leaflets and tendon in the chordae
tendineae (Lincoln et al., 2004; Rabkin-Aikawa et al., 2005).
These diversified valve structures arise from a common pool of
precursor cells in the ECs, and there is increasing evidence to
suggest that mechanisms required for valve precursor cell
diversification and differentiation are common with regulatory
hierarchies occurring in other connective tissues (de Lange et
al., 2004; Edom-Vovard and Duprez, 2004; Goldring et al.,
2006; Lange and Yutzey, 2006; Lincoln et al., 2004, 2006c).
Sox9 is an SRY-related transcription factor required for
cartilage formation and male sex determination (Bi et al., 1999;
Chaboissier et al., 2004; Goldring et al., 2006). Mutations of
human SOX9 cause campomelic dysplasia (CD), a disease
characterized by sex reversal and skeletal defects including
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with reduced Sox9 function have been used to determine
requirements for Sox9 during early and late stages of cartilage
formation (Akiyama et al., 2002; Bi et al., 1999; Bi et al., 2001;
Kist et al., 2002). During skeletal development, cartilage cell
lineage diversification is initiated in a population of mesench-
ymal precursor cells that condense and form pre-cartilaginous
aggregates (Goldring et al., 2006). Inactivation of Sox9 in early
stage cartilage precursor cells leads to a complete absence of
cartilage formation, indicating a requirement during early stages
of chondrogenesis (Akiyama et al., 2002). Later during
chondrogenic differentiation, Sox9 directly binds regulatory
elements of cartilage-specific genes including type II collagen
and Cartilage Link Protein (CLP) (Akiyama et al., 2002; Kou
and Ikegawa, 2004; Lefebvre and Smits, 2005; Ng et al., 1997).
Together, these studies demonstrate that Sox9 is required during
early cartilage cell lineage condensation and later for differ-
entiation of chondrogenic cell types.
In the developing heart, a common pool of progenitor cells
within the ECs develop into the heart valve leaflets and
supporting structure (Lincoln et al., 2004). There is initial
evidence from avian embryos that this progenitor pool
diversifies into distinct cell lineages that are subject to
regulatory pathways that also control cartilage and tendon
lineage development (Lincoln et al., 2006c). Sox9, primarily
associated with cartilage lineages, is expressed early in valve
precursor cells of the ECs, and expression is maintained in the
mature valve leaflets during later stages of development
(Akiyama et al., 2004; Lincoln et al., 2006a; Montero et al.,
2002; Rahkonen et al., 2003). The role of Sox9 during
valvulogenesis is not fully understood. Mice with germline
inactivation of Sox9 die between E11.5 and E12.5 and display
hypoplastic ECs that fail to complete EMT, suggesting a role
during initial stages of EC formation (Akiyama et al., 2004).
Sox9 is predominantly expressed throughout all stages of
valvulogenesis, however the functions of Sox9 during post-
EMT valve precursor cell maturation have not yet been defined.
Recently it has been shown that BMP signaling activates Sox9
expression and up-regulates cartilage-associated genes in
cultured avian mesenchyme valve precursor cells, consistent
with regulatory pathways reported in developing cartilage
(Lincoln et al., 2006a; Yoon and Lyons, 2004). However, the in
vivo function of Sox9 in valve precursor cell lineage
development, as well as formation and patterning of later
stage valvular structures, has not yet been determined.
In this study, we use conditional inactivation of Sox9 during
early and late stages of valvulogenesis to examine the
requirements for Sox9 during expansion and diversification of
valve precursor cells, as well in expression and organization of
ECM proteins characteristic of cartilage-like cell types in the
mature valves. The Sox9 floxed allele was inactivated in
endothelial cell derivatives that make up the EC using Tie2-cre,
or in a subset of differentiating valve cells using Type II
collagen a1-cre (Col2a1-cre) (Kist et al., 2002; Le and Sauer,
2001; Nagy, 2000). Loss of Sox9 function in endothelial-
derived cells shows that it is required for expansion anddiversification of the valve precursor cell pool following EMT.
Later inactivation of Sox9 with Col2a1-cre results in reduced
expression of cartilage matrix-associated markers and abnormal
ECM patterning in remodeling valve leaflets. Heart valve
calcification and increased ECM production were observed in
adult mice with Col2a1-cre mediated heterozygous loss of
Sox9. These data support an early role for Sox9 in EC cell
proliferation and later roles in differentiation, patterning and
homeostasis of mature valve structures.
Materials and methods
Generation of mice
Sox9 flox/flox female mice (Kist et al., 2002) were bred with Tie2-cre (Tek-cre)
or Col2a1-cre males (Jackson Laboratories) (Kisanuki et al., 2001;
Ovchinnikov et al., 2000) to generate heterozygous offspring that were
obtained at expected Mendelian ratios. Heterozygous Sox9 flox/+;Tie2-cre or
Sox9 flox/+;Col2a1-cre males were mated with Sox9 flox/flox females to generate
homozygous offspring (Sox9 flox/flox;Tie2-cre or Sox9 flox/flox;Col2a1-cre).
Alternatively, Sox9 flox/+;Col2a1-cre male mice were sacrificed at 1 or 3
months of age and the hearts collected in 1× phosphate buffered saline (PBS).
Timed embryonic (E) staged litters of mice were collected at E11.5–E18.5,
counting day E0.5 by evidence of a copulation plug for Sox9 flox/flox;Tie2-cre
(E11.5–E14.5 n=11 litters), Sox9 flox/flox;Col2a1-cre (E15.5–E18.5, n=14 litters)
and non-transgenic (NTG) FVBN mice (E13.0, E13.5, E18.5). Tie2-cre or
Col2a1-cre transgenic mice were crossed with Rosa26R-lacz (Rosa26R) reporter
mice to analyze β-galactosidase expression at embryonic stages E13.5 (Tie2-cre)
and E15.5–E18.5 (Col2a1-cre) (n=7 total litters) as previously reported (Lincoln
et al., 2004; Soriano, 1999). Genotyping for the Cre transgene and Sox9 floxed
alleles was performed by RT-PCR as previously described for embryonic yolk sac
or adult genomic DNA (Kist et al., 2002; Lincoln et al., 2004).
Histological analysis
E11.5–E14.5 whole embryos, or hearts from E18.5 embryos and adult
mice, were collected in 1× PBS and fixed in 4% paraformaldehyde (PFA)
overnight at 4 °C. Tissues were subsequently processed for either frozen or
paraffin embedding as previously described (Lincoln et al., 2006a). Frozen
sections were cut at 14 μm, mounted on Permafrost slides (Fisher), and in situ
hybridization was performed as previously reported (Lincoln et al., 2006a).
The Sox9 riboprobe was a kind gift from Dr. Ravi Elluru, and antisense probe
was generated as previously described (Elluru and Whitsett, 2004). In situ
probes for Msx-1 and Has-2 were kind gifts from Dr. James Martin (Ma et al.,
2005). Frozen 14 μm sections from E13.5 whose embryos in litters from
Tie2-cre mice bred with Rosa26R were used for X-gal staining as previously
reported (Lincoln et al., 2004; Stenman et al., 2003).
Paraffin-embedded tissue was sectioned at 5 μm and, following depar-
affinization and hydration through a graded ethanol series (100%, 95%, 75%,
50%), tissue was stained with Movat's Pentachrome, Von Kossa, Alcian blue, or
subject to immunohistochemistry (IHC). Procedures for Pentachrome and Von
Kossa staining have been previously described (Jones, 2001). Sections subject to
Alcian blue (0.1%/0.5% acetic acid, pH 3.1) were stained for 15 min, rinsed in
water, counterstained in 15% nuclear fast red (Vectastain), dehydrated and
mounted in Cytoseal (Richard Allen Scientific). IHC for β-galactosidase
(Abcam, 1:200), Sox9 (Santa Cruz, 1:200), phospho-histone H3 (pHH3) (Upstate,
1:100), cleaved caspase-3 (Cell Signaling, 1:200) and β-catenin (Signal
Transduction, 1:200) was performed using diaminobenzidine (DAB) colorimetric
analysis following the manufacturer's instructions (Santa Cruz). In addition,
boiling tissue sections for 10 min in 0.1 M sodium citrate was required for
antigen retrieval and detection of β-catenin. To determine cell proliferation, the
number of pHH3 positive nuclei was calculated as a percentage of the total
number of nuclei in 15 sections from 3 independent embryos for each group. The
value of the total number of cells in E11.5 and E12.5 in these sections was
averaged and statistical significance of observed differences was determined by
Student's t-test (P<0.05).
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Iowa, 1:5), tenascin (Chemicon, 1:400), β-galactosidase (Abcam, 1:200) and
type II collagen (Abcam, 1:200) were detected using immunofluorescence (IF).
Following deparaffinization, tissue sections for IF were incubated with blocking
solution (1% bovine serum albumin, 0.1% cold water fish skin gelatin, 0.1%
Tween-20, 0.05% NaN3/PBS) for 1 h at room temperature. Tissues were
incubated overnight at 4 °C with primary antibodies in 1:1 block/PBS using
Coverwell chamber slides (Grace Biolabs). Following incubation, sections were
washed in 1× PBS and incubated with corresponding Alexa fluorescent-
conjugated secondary antibodies (Molecular Probes, 1:100/PBS) and TOPRO-3
(Molecular probes, 1:1000) for 1 h at room temperature. Sections were washed
thoroughly in 1× PBS and mounted in hard set Vectashield (Vectorlabs). For
double staining, tissue sections were incubated overnight with both primary
antibodies, while fluorescent secondary antibodies were applied separately as
described. Fluorescent images were analyzed using the Nikon PCM2000
confocal microscope and Simple PCI software. Immuno- and cytochemical
stained sections were visualized with an Olympus BX60 microscope and
captured using Advanced SPOT image software.
Quantitative analysis of histological changes
Immunoreactivity of CLP and tenascin in IF double stained tissue sections
was measured using Metamorph software (version 6.3, Universal Imaging,
Media, PA) and recorded as a percentage of the calculated total EC area. This
analysis was performed on hearts from 3 independent Sox9 flox/+;Tie2-cre and 3
Sox9 flox/flox;Tie2-cre E12.5 embryos. Based on the position of the ventricles and
great vessels, 6 comparable sections selected from throughout the EC of control
and mutant mice were analyzed, and immunoreactivity values were averaged.
Statistical significance of observed differences was determined using Student's
t-test (P<0.05).
Changes in valve leaflet area were determined in hematoxylin and eosin
stained sections from 2 Sox9 flox/+;Col2a1-cre+/– and 2 control Sox9 flox/+;Fig. 1. Sox9 and Cartilage Link Protein are expressed in endocardial cushion
Immunohistochemistry was used to examine expression patterns of Sox9 (A, C) and C
leaflets at E18.5 (C, D). (A) Nuclear Sox9 expression is detected throughout valv
expression is also detected in the matrix associated with Sox9 positive cells within th
(arrows). At E18.5, Sox9 (C) and CLP (D) expression is detected in the maturing s
observed on the atrial surface (arrow) and ventricular surface with enhanced expressi
myocardium (*). tv, tricuspid valve; IVS, interventricular septum; RA, right atrium;Col2a1-cre –/– mice at 3 months of age. Using NIH Image J (version 1.32), the
area of each valve leaflet in the AV canal and OFTwas measured in 12 sections
taken from comparable regions throughout the respective hearts. The total valve
leaflet area was measured for each valve within the AV canal and OFT and
includes the area from where the leaflet begins to protrude from the mural wall,
to where the leaflet rejoins (outlined in Fig. 7C and E). The average size of the
AVand OFT leaflets on each tissue section was calculated and reported as a fold
change over control (Sox9 flox/+;Col2a1-cre –/–) measurements. Based upon
multiple sections (12) from 2 control and 2 Sox9 flox/+;Col2a1-cre+/– mice,
statistical significance was calculated using Student's t-test (P<0.01).Results
Sox9 and Cartilage Link Protein are expressed during early
and late stages of murine valvulogenesis
Immunohistochemistry was used to determine the expres-
sion patterns of Sox9 and Cartilage Link Protein (CLP)
during cell lineage diversification (E13.5) and differentiation
stages (E18.5) of valvulogenesis in the mouse. Nuclear-
specific Sox9 protein expression is observed in the majority
of valve precursor cells within the mural (arrowheads) and
septal (arrows) ECs at E13.5 (arrows, Fig. 1A), but not in the
developing myocardium (*, Figs. 1A, C). This is in contrast
to avian embryos, which exhibited more localized expression
of sox9 in AV EC at comparable stages (Lincoln et al.,
2006a). However, there are some nuclei that are not positive
for Sox9 in the E13.5 mouse valve primordia which iss and primitive heart valve leaflet structures during mouse valvulogenesis.
LP (B, D) in the endocardial cushions at E13.5 (A, B) and developing heart valve
e precursor cells of the central (arrows) and mural (arrowhead) ECs. (B) CLP
e mural EC (arrowhead) and the more lateral ventricular region of the central EC
eptal and mural tricuspid valve leaflets (arrows), with predominant expression
on at the distal tips (arrowheads). Notably, Sox9 and CLP are not detected in the
LV, left ventricle; CLP, Cartilage Link Protein.
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detected by IF, CLP protein is expressed predominantly on
the right and left sides of the central EC (arrows) and also
within the mural ECs (arrowheads), where Sox9 expression is
also apparent. In the core of the central EC that overlies the
interventricular septum (IVS), there is less CLP expression
than in the more lateral regions that form the valve primodia
(arrows, Fig. 1B). At E18.5 in the tricuspid valve, Sox9
expression is apparent on both the atrial (arrows) and
ventricular (arrowheads) surfaces of the elongating mural
and septal heart valve leaflets (Fig. 1C). Similarly at E18.5,
expression was undetected in the myocardium (*, Fig. 1C). At
this stage, CLP expression is also observed on the atrial
surface (arrows, Fig. 1D) and ventricular aspect, including the
distal tips, of the valves (arrowheads, Fig. 1D). Similar to
Sox9, CLP expression is highly expressed along the atrial
surface of the valve leaflets (arrows, Figs. 1C, D), but
expression of both also is apparent on the ventricular surfaces
especially at the distal tips. These expression studies show
that Sox9 and CLP are expressed in overlapping regions
of the EC and developing heart valve leaflets during
valvulogenesis.
Sox9 is required during early stages of heart valve
development for formation of valve primordia
Tie2-cre and Col2a1-cre transgenes were used for targeted
conditional inactivation of Sox9 in Tie2- and Col2a1-
expressing cell types during early and late stages of valve
development, respectively. The Tie2-cre transgene is ex-
pressed in endothelial cells prior to EMT and drives re-
combination throughout derived mesenchyme cells that
contribute to the mature valves (de Lange et al., 2004;
Lincoln et al., 2006a). Consequently, Sox9 flox/flox;Tie2-cre
mice die between E11.5 and E14.5 displaying pericardial
edema (arrow, Fig. 2B) and increased blood pooling (arrow-
head, Fig. 2B) compared to controls (arrow and arrowhead,
Fig. 2A). Upon histological examination Sox9 flox/flox;Tie2-cre
mice also show obvious defects in valve maturation. At E13.5
in Tie2-cre;ROSA26R mice, recombination occurs in the
majority of valve precursor cells that populate the valve
primordia, as detected by X-gal staining (arrows, Fig. 2C). At
this stage in wild-type embryos, Sox9 also is expressed
broadly in the valve primordia (arrows, Fig. 2D) consistent
with a previous report (Montero et al., 2002). Loss of Sox9
protein expression in Sox9 flox/flox;Tie2-cre mice (arrow, Fig.
2F) compared to Sox9 flox/+;Tie2-cre controls (arrows, Fig. 2E)
indicates efficient recombination and targeting of the Sox9
locus with Tie2-cre in valve precursor cells of the ECs.
Histologically, Alcian blue staining indicates hypoplastic ECs
in Sox9 flox/flox;Tie2-cre mice that fail to elongate and form AV
valve primordia at E13.5 (arrows, Figs. 2G, H). ECs within
the OFT of Sox9 flox/flox;Tie2-cre mice also appear grossly
reduced in size (data not shown). In the AV canal there is
malalignment of the atrial septum (as) (arrowhead, Figs. 2G,
H), although the septum does meet the ECs in more distal
tissue sections (data not shown). These data support a role forSox9 in the formation of distinct mitral and tricuspid valve
primordia in the AV canal.
Sox9 is required during later stages of valvulogenesis for heart
valve leaflet maturation
Inactivation of Sox9 during later stages of valve develop-
ment was achieved using the Col2a1-cre transgene, shown
previously to recombine in chondrogenic-derived cells
(Ovchinnikov et al., 2000). Col2a1-cre recombination was
detected in embryos of Col2a1-cre;ROSA26R mice using X-
gal staining. Cre recombination is first observed at E15.5 and
is shown at E18.5 along the atrial and more predominantly on
the ventricular surfaces of the primitive heart valve leaflets
(Fig. 3A). At this time, Sox9 expression is observed on both
atrial and ventricular surfaces of the mural and septal tricuspid
valve leaflets (Figs. 1C, 3B, C). Following recombination,
Sox9 flox/flox;Col2a1-cre mice show reduced nuclear Sox9
protein expression (arrows, Fig. 3D) predominantly on the
ventricular surface of the valve leaflets where recombination
has occurred (arrows, Fig. 3D). Sox9 protein expression is still
apparent on the atrial surface where there is less activity of the
Col2a1-cre transgene (arrowhead, Fig. 3D). Sox9 flox/flox;
Col2a1-cre mice die at birth due to presumed respiratory de-
fects, and therefore heart valves were examined in embryos har-
vested at E18.5 (Akiyama et al., 2002). At E18.5, Sox9 flox/flox;
Col2a1-cre mice display thickened heart valve leaflets with
apparently reduced Alcian blue staining (arrows, Fig. 3F),
compared to the long, thin, glycosaminoglycan-rich valve leaflets
of Sox9 flox/+;Col2a1-cre control mice (arrows, Fig. 3E). In
addition, the width of the interventricular septum (IVS) of
Sox9 flox/flox;Col2a1-cre mice is increased, which may be related
to compromised cardiac function (Figs. 3E, F) (Baudino et al.,
2006). The morphological valve defects observed using Col2a1-
cre suggest a role for Sox9 in maturation and function of the
valve leaflets during later stages of valve development. The
differential phenotypes resulting from loss of Sox9 in valve
precursor cells (Tie2-cre), or a subset of remodeling valve cells
(Col2a1-cre), indicate that Sox9 may have distinct functions
during early and late stages of valvulogenesis.
Sox9 flox/flox;Tie2-cre mice have hypoplastic endocardial
cushions associated with decreased cell proliferation
To determine the developmental mechanisms underlying
hypoplastic ECs observed in E13.5 Sox9 flox/flox;Tie2-cre hearts,
cell proliferation and apoptosis were examined at E11.5 and
E12.5 during stages of EC maturation (Figs. 4A, B). EMT has
occurred in Sox9 flox/flox;Tie2-cre mice at E11.5 as indicated by
the presence of mesenchymal cells in the EC (arrows, Figs. 4A,
B). However the number of cells populating the cushion area is
significantly reduced (Figs. 4A–C) and the cushion morphology
is abnormal as indicated by Alcian blue staining. At E12.5, cell
proliferation within ECs of Sox9 flox/flox;Tie2-cre mice is reduced
by 75%, as indicated by quantitative analyses of IHC of phospho-
histone H3 (pHH3) in valve precursor cells compared to controls
(Figs. 4D–F). Notably, proliferation in the myocardium, where
Fig. 2. Sox9 flox/flox;Tie2-cre mice have embryonic heart failure and display hypoplastic endocardial cushions. (B) Grossly, Sox9 flox/flox;Tie2-cre mice display
pericardial edema (arrow) and increased blood pooling (arrowhead), compared to controls (A) at E12.5. At the cellular level, X-gal staining and in situ hybridization
were performed on tissue sections of heart valve structures at E13.5 in embryos from Tie2-cre mice bred with ROSA26R to determine Tie2-cre-mediated
recombination with Sox9 in the developing heart valves. (C) Tie2-cre recombination is detected throughout the valve primordia at E13.5, consistent with Sox9
expression (arrows, D). (E) Compared to control Sox9 flox/+;Tie2-cre control mice, Sox9 protein expression (arrows) is diminished in ECs of Sox9 flox/flox;Tie2-cremice
(F) indicative of recombination. Alcian blue staining was used to indicate proteoglycans within the heart valve structures in control Sox9 flox/+;Tie2-cre (G) and mutant
Sox9 flox/flox;Tie2-cre (H) mice. Arrows indicate hypoplastic EC in Sox9 flox/flox;Tie2-cremice (D) compared to controls (C). Arrowheads indicate incomplete formation
of the atrial septum (as). IVS, interventricular septum; mv, mitral valve; tv, tricuspid valve; LV, left ventricle; RV, right ventricle.
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Fig. 3. Heart valve leaflets in Sox9 flox/flox;Col2a1-cre mice are abnormal with reduced Alcian blue staining. Col2a1-cre recombination (A) is observed in a subset of
cells on the atrial (A) and ventricular (V) surfaces of the valve leaflets at E18.5 in Col2a1-cremice bred with Rosa26R. (B) At this time, Sox9 expression is detected by
in situ hybridization throughout the valve leaflet structures (arrows). (C) Compared to Sox9 flox/+;Col2a1-cre control mice, nuclear Sox9 protein expression is
diminished on the ventricular aspect of valve leaflets of Sox9 flox/flox;Col2a1-cre mice (arrow) (D), although expression remains on the atrial surface where
recombination has not taken place (arrowhead). Heart valve leaflets of Sox9 flox/flox;Col2a1-cre mice (F) are abnormal at E18.5 and Alcian blue staining is reduced
compared to Sox9 flox/+;Col2a1-cre control mice (E). IVS, interventricular septum; mv, mitral valve; tv, tricuspid valve.
125J. Lincoln et al. / Developmental Biology 305 (2007) 120–132recombination does not occur, is unchanged (arrowhead, Figs.
4D, E). Changes in cleaved caspase-3 activity, an indicator of
apoptotic cells, were not observed in ECs of Sox9 flox/flox;Tie2-cre
mice (data not shown). These data provide evidence for a
requirement for Sox9 in cell proliferation of mesenchyme cells
after initiation of EMT to expand the heart valve progenitor cell
pool.
The endocardial cushions of Sox9 flox/flox;Tie2-cre mice have
altered ECM protein expression and distribution
Previous work has shown that avian AV valve progenitor
cells have the potential to diversify into cartilage- and tendon-
like cell types (Lincoln et al., 2006a). CLP and tenascin
immunoreactivity was examined as indicators of valve cell
differentiation in ECs from Sox9 flox/flox;Tie2-cre mice.
Although not exclusive to cartilaginous and tendinous cell
types, these markers are differentially expressed in the
developing valves and are therefore indicators of valvedifferentiation and ECM organization (Lincoln et al., 2006a).
In control embryos, tenascin expression (arrows, Fig. 5A) is
localized in the distal regions and ventricular aspect of the
cushion (highlighted in white). Normally, CLP is more widely
expressed in lateral aspects of the central EC (arrowheads, Fig.
5C) and is not detected at the central atrial aspect of the
cushion (*). In the Sox9 flox/flox;Tie2-cre embryos, the ECs are
strikingly much smaller (Figs. 5B, D, F). Associated with the
change in EC size and morphology, the relative distribution of
tenascin and CLP in Sox9 flox/flox;Tie2-cre ECs is altered
compared to controls. Tenascin expression is no longer
predominant in ventricular regions, but is observed in a more
atrial location (arrows, Figs. 5B, F). In contrast, CLP
expression continues to be widespread throughout the core of
the central cushion (arrowheads, Figs. 5D, F). The immuno-
positive areas for tenascin or CLP were quantified as a
percentage of the outlined EC area of control and Sox9 flox/flox;
Tie2-cre embryos to determine changes in the relative
distribution of these extracellular matrix proteins (Fig. 5G).
Fig. 4. Valve precursor cells of Sox9 flox/flox;Tie2-cre mice have decreased proliferation. Alcian blue staining of histological sections of E11.5 Sox9 flox/+;Tie2-cre
(A) and Sox9 flox/flox;Tie2-cre (B) embryos shows abnormal morphology and reduced size of EC lacking Sox9 expression indicated by arrows. Phospho-histone H3
(pHH3) immunohistochemistry was used to detect proliferating cells in EC tissue sections from Sox9 flox/+;Tie2-cre (D) and Sox9 flox/flox;Tie2-cre (E) mice at E12.5.
(C) Quantitative analyses were performed to detect significant changes in the average number of mesenchymal cells in tissue sections of the EC from Sox9 flox/flox;
Tie2-cre mice compared to Sox9 flox/+;Tie2-cre controls at E11.5 and E12.5. (F) The number of nuclei stained positive for pHH3 in each tissue section of EC from
E12.5 Sox9 flox/+;Tie2-cre and Sox9 flox/flox;Tie2-cre mice was used to calculate a proliferative index represented as a percentage of the total number of nuclei. Note
proliferation is reduced in Sox9 flox/flox;Tie2-cre mice. (F). A, atrium; V, ventricle; RA, right atrium; IVS, interventricular septum.
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tenascin immunoreactivity is increased by approximately 2-
fold in the EC of Sox9 flox/flox;Tie2-cre mice compared to
controls, but the percentage of EC area positive for CLP
expression was unchanged. The altered proportions of EC
area that express each of these matrix proteins likely reflect a
significant disruption in ECM distribution and patterning in
the Sox9 flox/flox;Tie2-cre mice. By gross examination, markers
of undifferentiated EC mesenchyme cells including Msx-2,
Has-2 and β-catenin were apparently unaffected by the
loss of Sox9 (data not shown). Thus, loss of Sox9 in EC
mesenchyme specifically affects differentiation and patterning
of the valve primordia.
Sox9 flox/flox;Col2a1-cre mice have reduced expression of
cartilage-associated proteins, CLP and type II collagen and
exhibit altered ECM patterning and organization
In differentiating cartilage, Sox9 regulates expression of
structural genes including type II collagen and CLP (Bell et
al., 1997; Kou and Ikegawa, 2004; Ng et al., 1997).
Immunofluorescence was used to determine the expression
patterns of type II collagen (Figs. 6A, B), CLP (Figs. 6C, D)
and elastin (Figs. 6E, F) in Sox9 flox/flox;Col2a1-cre valves
(Figs. 6B, D, F) compared to controls at E18.5 (Figs. 6A, C,E). In control mice, type II collagen is expressed predomi-
nantly on the ventricular surfaces of heart AV valve leaflets
(arrows, Fig. 6A). In contrast, type II collagen expression in
the AV heart valves is undetected in Sox9 flox/flox;Col2a1-cre
mice (arrows, Fig. 6B). CLP expression is observed more
broadly in the valve leaflets of control mice (arrowhead, Fig.
6C). In Sox9 flox/flox;Col2a1-cre mice, CLP expression is
diminished, especially on the valve leaflet ventricular surfaces
and distal tips where Col2a1-cre is active (arrow, Fig. 6D).
However, expression is not completely absent (arrowhead,
Fig. 6D), likely due to remaining Sox9 protein in the more atrial
surfaces where Col2a1-cre and Sox9 do not overlap (Fig. 3D).
Expression of CLP was also dramatically reduced in the OFT
valves (data not shown). The expression pattern of elastin, an
ECM protein not associated with Sox9 or cartilage lineage
development, was examined in control and Sox9 flox/flox;Col2a1-
cre mice (Figs. 6E, F). Normally, elastin is expressed primarily
along the atrial surface of the valve leaflet (arrows, Fig. 6E). In
addition to the normal elastin expression observed on the atrial
surface of the valve leaflets in Sox9 flox/flox;Col2a1-cre mice
(arrows, Fig. 6F), ectopic expression is also noted on the
ventricular surface of the enlarged valve leaflets (arrowhead,
Fig. 6F). However, it is noted that the overall expression of
elastin is lower in mouse valves compared to previous reports of
avian valves and is likely due to the differential functional
Fig. 5. Tenascin and CLP expression is altered in Sox9 flox/flox;Tie2-cremice. (A, B) Immunofluorescence staining of tenascin (A, B) and CLP (C, D) was used to show
ECM protein expression in tissue sections of ECs (highlighted by white lines) from Sox9 flox/+;Tie2-cre (A, C, E) and Sox9 flox/flox;Tie2-cre (B, D, F) mice at E12.5.
Tenascin-positive regions are indicated by arrows and CLP-positive regions are indicated by arrowheads. (D) The atrial aspect of the central EC where CLP is not
expressed is indicated by (*). Merged images from panels A–D are shown in panels E, F. The percent area of the immunoreactivity of CLP and tenascin within the
central EC is reported in panel G. Error bars represent standard error of the mean, and statistical significance (*) is calculated by Student's t-test compared to Sox9 flox/+;
Tie2-cre mice (P<0.05; n=3). IVS, interventricular septum; LA, left atrium; RV, right ventricle.
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1994). These observations of the Sox9 flox/flox;Col2a1-cre mice
indicate that the overall organization of the stratified ECM
layers within the valve leaflets of Sox9 flox/flox;Col2a1-cre mice
is affected by loss of Sox9 in a subpopulation of cells.
Collectively, these data show that ECM proteins regulated by
Sox9 in cartilage are decreased in the remodeling heart valves of
Sox9 flox/flox;Col2a1-cre mice and support the hypothesis that
Sox9 is required for differentiation of valve cell lineages and
organization of the ECM.Adult heart valve leaflets from Sox9 flox/+;Col2a1-cre mice are
thickened and show calcium deposits
Changes in Sox9 expression have been implicated in forms
of adult degenerative heart valve disease associated with
leaflet calcification (Caira et al., 2006). ECM distribution and
calcification of heart valve structures were examined in
Sox9flox/+;Col2a1-cre+/– adult mice usingMovat's Pentachrome
and Von Kossa staining, respectively. During embryogenesis
and early stages of adult life, the heart valves of Sox9 flox/+;
Fig. 6. Type II collagen and CLP expression are reduced in Sox9 flox/flox;Col2a1-cre mice. Immunostaining for type II collagen (A, B), CLP (C, D) and elastin (E, F)
was used to determine ECM expression and organization in Sox9 flox/+;Col2a1-cre (A, C, E) and Sox9 flox/flox;Col2a1-cre (B, D, F) mitral valve mural and septal
leaflets at E18.5 (outlined in white). The expression of type II collagen (A) and CLP (C) in the mural and septal valve leaflets (arrows) of Sox9 flox/+;Col2a1-cremice is
diminished in Sox9 flox/flox;Col2a1-cremice (B, D). (E) Normal elastin expression is detected on the atrial surface of mitral valve mural and septal leaflets of Sox9 flox/+;
Col2a1-cre embryos. (F) Elastin expression is also observed on the atrial surface of valve leaflets from Sox9 flox/flox;Col2a1-cre embryos, but ectopic expression is
additionally noted on the ventricular surface of the septal leaflet (arrowhead, F). mv, mitral valve; IVS, interventricular septum.
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calcification as indicated by an absence of Von Kossa stain (data
not shown). However, from 3 months of age, increased Von
Kossa staining, indicative of mineral deposits, was apparent in
AV and OFT heart valve leaflets in 75% of the Sox9 flox/+;
Col2a1-cre+/– mice (arrows, Fig. 7B) compared to lower
frequency in Sox9 flox/+;Col2a1-cre−/− control mice (37.5%)(Fig. 7A). In control mice that exhibited Von Kossa staining,
the extent of mineralization is less and encompasses a smaller
fraction of the valve surface area by gross analysis compared
to mutant mice. Notably Von Kossa staining was not observed
in cardiac structures that do not express Sox9, including the
aortic root of Sox9 flox/+;Col2a1-cre+/– mice (data not shown).
ECM expression and distribution were assessed by Movat's
Fig. 7. Heart valves from adult Sox9 flox/+;Col2a1-cre+/– mice are thickened and calcified. Von Kossa stain was used to examine calcium deposition in mitral valve
(MV) leaflets of control Sox9 flox/+;Col2a1-cre−/− (A) and Sox9 flox/+;Col2a1-cre+/− (B) mice at 4 months of age. Von Kossa stains calcium deposits black, as indicated
in Sox9 flox/+;Col2a1-cre+/− mice (arrows, B). Movat's Pentachrome staining was used to show ECM distribution and organization in the MV (C, D) and semilunar
(OFT) (E, F) valve leaflets of control and Sox9 flox/+;Col2a1-cre+/− mice. Morphometric analyses show thickened valve leaflets in Sox9 flox/+;Col2a1-cre+/− (D, F)
mice compared to controls (C, E). Quantitative analysis of the fold change in the AV (G) and OFT (H) leaflet area (outlined in black) of Sox9 flox/+;Col2a1-cre+/– mice
over controls is shown. Statistical significance (*) was performed by Student's t-test (P<0.01). MV, mitral valve; IVS, interventricular septum; OFT, outflow tract.
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(OFT) valve leaflets of Sox9 flox/+;Col2a1-cre+/– and control
mice (Figs. 7C–F). The AV and OFT valve leaflet area of
Sox9 flox/+;Col2a1-cre+/– mice is significantly greater than
control valves (Figs. 7G, H). This is associated with an
increased abundance of proteoglycans at the tip of the valve
leaflets, as indicated by Alcian blue staining (arrows, Figs. 7C–
H). These cytochemical analyses demonstrate that Sox9 flox/+;
Col2a1-cre+/– mice show characteristics of heart valve disease
associated with leaflet thickening, calcium deposition and
altered ECM production.
Discussion
Recent studies have shown conservation of cartilage, tendon
and bone regulatory hierarchies with heart valve development
(Lincoln et al., 2006a,c). During cartilage formation, Sox9 is
required early in precursor cells during mesenchyme cell
condensation and later during chondrogenic lineage differentia-
tion (Lefebvre and Smits, 2005). In the developing heart, Sox9
is expressed during early and late stages of valve development
and, in avian embryos, Sox9 expression is coordinately induced
with aggrecan in response to BMP2 signaling in multipotential
valve progenitor cells (Lincoln et al., 2006a). The requirements
for Sox9 in mouse heart valve development in vivo were
examined using the Cre/loxP system to target Sox9 inactivation
early in endothelial-derived cells of the EC (Tie2-cre) (Kisanuki
et al., 2001) and later in a subset of cells within the mature valve
leaflets using Col2a1-cre, which also is expressed in differ-
entiating cartilage cell lineages (Ovchinnikov et al., 2000). In
Sox9 flox/flox;Tie2-cre embryos, initial EMT and formation of the
EC mesenchyme occur, however, mice die between E11.5 and
E14.5 with hypoplastic ECs, and consequently a decrease in the
number of valve precursor cells. ECM expression and
organization also are disrupted in Sox9 flox/flox;Tie2-cre mice,
as indicated by an abnormal relative distribution of tenascin
expression. Together these data support roles for Sox9 during
expansion and differentiation of heart valve precursor cells.
Targeted inactivation of Sox9 in a subpopulation of valve cells
during later stages of remodeling in Sox9 flox/flox;Col2a1-cre
mice leads to thickened valve leaflets, with reduced expression
of type II collagen and CLP, which are regulated by Sox9 in
cartilage. In addition, overall ECM distribution and organiza-
tion of the valve leaflets are disrupted in Sox9 flox/flox;Col2a1-
cre mice, as indicated by ectopic elastin expression on the
ventricular surface of the valve leaflets. These data provide
evidence for a later role for Sox9 during differentiation and
remodeling of heart valve structures. Together these studies
demonstrate early functions for Sox9 in valve progenitor cell
proliferation and later functions in valve differentiation, ECM
organization and homeostasis.
Sox9 is required for proliferation and diversification of valve
progenitor cells
ECs of Sox9 flox/flox;Tie2-cre mice form initially, but are
hypoplastic with abnormal distribution of ECM proteinexpression. Previously, Akiyama and colleagues have shown
that germline inactivation of Sox9 leads to a reduced number of
valve precursor cells due to insufficient EMT (Akiyama et al.,
2002). The Tie2-cre transgene used in this study has enabled us
to examine the effects of loss of Sox9 on later events of cushion
cell proliferation and differentiation (Lincoln et al., 2004). In
Sox9 flox/flox;Tie2-cre embryos, endothelial cells are able to
undergo EMT, as indicated by the presence of mesenchymal
cells in the EC at E11.5. However, proliferation of EC cells after
EMT is significantly reduced, with no apparent change in cell
death, leading to a diminished progenitor pool of valve
precursor cells. These findings are in contrast to the requirement
of Sox9 in EMT reported by Akiyama and are likely due to
kinetics of the Cre-mediated recombination and Sox9 protein
turnover in Sox9 flox/flox;Tie2-cre mice. Therefore the targeted
loss of Sox9 in EC mesenchymal cells after EMT demonstrates
an additional function of Sox9 in cell proliferation and
expansion of the heart valve progenitor pool (Akiyama et al.,
2004; Goldring et al., 2006; Lefebvre and Smits, 2005).
Valve precursors isolated from avian embryos differentially
express ECMmarkers characteristic of cartilage and tendon cells
within diversified subsets of differentiating cells (Lincoln et al.,
2004). The localization of these cell lineages remains distinct as
cartilage-like cells occupy the valve leaflet and tendon-like cells
are observed in the supporting chordae (Lincoln et al., 2004).
Previous work indicated that a balance of cartilage and tendon-
like cell lineages originates from this cell population depending
on the exposure to BMP and FGF signaling (Lincoln et al.,
2006c). In cultured avian valve progenitor cells, BMP2 treatment
induces expression of Sox9 and chondrogenic-associated gene
markers and promotes diversification of cartilage-like cell
lineages (Lincoln et al., 2006a). In mice with targeted loss of
Sox9 at different stages of valve development, expression and
localization of tenascin, type II collagen and CLP are altered.
Further studies are necessary to determine definitively if these
alterations in ECM gene expression are the result of aberrant
valve cell lineage diversification. However, these data support a
role for Sox9 in valve cell precursor differentiation and
patterning in mouse embryos.
Sox9 is required for normal valve patterning and expression of
type II collagen and CLP
Reduced expression of Sox9 target genes type II collagen
and CLP was observed in heart valves of Sox9 flox/flox;Col2a1-
cremice. The Col2a1-cre transgene targets Sox9 inactivation in
a subset of cells at the edges of the valve leaflets from E15.5.
The reduced expression of type II collagen and CLP observed in
Sox9 flox/flox;Col2a1-cre embryos by E18.5 suggests that Sox9 is
required during this later developmental stage for expression of
these genes, which have previously been demonstrated to be
direct targets of Sox9 in cartilage progenitor cells (Kou and
Ikegawa, 2004; Ng et al., 1997). In cartilage of the developing
limbs, Sox9 is required early for lineage determination and later
for differentiation and expression of type II collagen (Akiyama
et al., 2002; Bi et al., 1999). In the differentiating valves, Sox9
is similarly required for type II collagen expression, but it has
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type II collagen and CLP expression in differentiating heart
valves is consistent with a requirement for Sox9 in the
differentiation of a valve cell population with characteristics
of cartilage. The observation that loss of Sox9 during early
stages of valvulogenesis does not result in reduced CLP
expression may be indicative of distinct regulatory mechanisms
acting in the primitive valve progenitor cells. These studies
provide further evidence for conserved regulatory relationships
between signaling pathways, transcription factors and down-
stream target genes in developing cartilage and differentiating
heart valve cell lineages.
Mature valve leaflets of vertebrates are composed of fibrosa
(collagen), spongiosa (proteoglycan) and atrialis (elastin) layers
which are not fully apparent until after birth (Hinton et al.,
2006). In general the ECM layers of avian and human valves
are relatively thickened with increased matrix deposition
relative to mouse valves, but the overall organization and
structure is conserved (Hinton et al., 2006). It has not yet been
determined that these different matrix cell layers are produced
by distinct valve cell lineages, but differential expression
patterns of regulatory genes and their downstream targets
during chicken and mouse valve development support this idea.
In the Sox9 flox/flox;Col2a1-cre mice, CLP expression is reduced
throughout the heart valve leaflets and elastin expression is
abnormally expressed on the ventricular surface of AV valves
at E18.5 which likely reflects an overall disruption in ECM
distribution and patterning of the valves. It is possible that these
alterations in valve patterning are secondary to compromised
function since they occur in cells that do not express the
Co2a1-cre transgene. Similarly the thickened IVS observed in
Sox9 flox/flox;Col2a1-cre mice is a likely secondary effect of
cardiac dysfunction and was also observed in mice with altered
collagen expression in the developing valves (Lincoln et al.,
2006b). These changes in valve structure and chamber
morphology with loss of Sox9 in a subset of valve cells
underscore the importance of the distribution of specific types
of ECM proteins that form matrices with distinct biochemical
and mechanical characteristics for development and mainte-
nance of normal heart valve structure and function.
Sox9 and heart valve disease
Defects in heart valve structures represent 20–30% of all
congenital cardiovascular malformations (Hoffman and
Kaplan, 2002; Supino et al., 2004). These anomalies can lead
to valve disease apparent as heart valve leaflet thickening (or
myxomatous valves), degeneration and calcification in adults
(Lincoln et al., 2006c; Rabkin-Aikawa et al., 2005; Schoen and
Levy, 2005). These defects are associated with changes in
ECM organization and increased mineralization with detri-
mental effects on valve function (Garg et al., 2005; Lincoln et
al., 2006c; Schoen and Levy, 2005). However, the underlying
causes of disorganized and ectopic ECM or mineralization that
occur during valve pathogenesis are poorly understood. There
is increasing evidence to support developmental origins of
heart valve disease manifested later in life (Garg et al., 2005;Hinton et al., 2006; Lincoln et al., 2006c). This study has
shown a requirement for Sox9 during heart valve development.
In addition, reduced Sox9 function in Sox9 flox/+;Col2a1-cre
mice is associated with histological changes characteristic of
diseased valves, including an increase in valve leaflet area and
calcium deposition. The heart valves of Sox9 flox/+;Col2a1-cre
mice with localized reduction of Sox9 function are apparently
normal at birth, but undergo histological changes over several
months during post-natal stages. It is possible that the
progressive degeneration of the valves in these animals is
exacerbated by compromised heart function and hemody-
namics, as is often the case in human heart disease. Therefore
these mice are a potentially useful model for studies of the
pathogenesis of valve disease.
The mechanisms of the altered ECM homeostasis associated
with reduced Sox9 function are not clear, but in human patients,
elevated levels of Sox9 have been reported in degenerative and
calcified human mitral valves (Caira et al., 2006). This
observation is evidence that precise regulation of Sox9 is
required for normal valve homeostasis and that altered Sox9
function may be related to valve disease associated with
connective tissue dysfunction. In developing cartilage, loss of
Sox9 function results in premature ectopic mineralization of
bone and changes in ECM organization and distribution. It is
possible that increased calcium deposition observed in valves
from mice with reduced Sox9 may be related to similar
pathogenic mechanisms and that aberrations in Sox9 function
may underlie certain types of calcified valve disease. Interest-
ingly, cardiac phenotypes, including septal defects, are reported
in 22% of CD patients, supporting a role for Sox9 in normal
heart development (Houston et al., 1983; Mansour et al., 1995).
Likewise, this study has identified critical roles for Sox9 in
mouse heart valve development in vivo. Therefore, histological
analysis of heart valve ECM homeostasis in CD patients may be
informative and unveil previously unappreciated forms of valve
defects. Collectively, Sox9 is required for early and late stages
of heart valve formation through mechanisms similar to those
previously described in cartilage formation. In addition, there is
evidence to suggest that Sox9 may contribute to mechanisms of
congenital heart valve disease.
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